You are here: Industry Insights > Glenmark

News List

Glenmark and SaNOtize introduce nasal spray to treat Covid-19 in India Pharmaceutical-Technology
February 10, 2022
Earlier, Glenmark received manufacturing and marketing approval from the Drugs Controller General of India for NONS.
Glenmark gets US FDA nod for nasal spray to treat seasonal allergic rhinitis ExpressPharma
January 14, 2022
With this NDA approval, the company looks forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis...
Glenmark inks agreement with SaNOtize to commercialise nasal spray for COVID-19 treatment in India and other Asian markets expresspharma
August 03, 2021
Nitric oxide (NO) has anti-microbial properties with a direct proven effect on SARS-CoV-2.
Glenmark gets USFDA nod for generic lung cancer drug expresspharma
June 28, 2021
Glenmark Pharmaceuticals yesterday said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer, in the American market.
Glenmark launches Tiogiva, tiotropium bromide dry powder inhaler in UK expresspharma
June 16, 2021
Glenmark Pharmaceuticals has launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name – Tiogiva, in the UK for the treatment of chronic obstructive pulmonary disease (COPD).
Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu) expresspharma
June 09, 2021
PMS interim data revealed no new safety signals or concerns till date and safety is in line with known side effects of the drug.
Glenmark gets US FDA approval for Theophylline ER Tablets, 300 mg and 450 mg expresspharma
June 07, 2021
Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg.
Glenmark launches Rufinamide Tablets USP, 200 mg and 400 mg expresspharma
June 02, 2021
It is indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) along with other medicines.
Glenmark gets US FDA nod for Icatibant injection, 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe expresspharma
May 25, 2021
This marks Glenmark’s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.
Glenmark launches Ryaltris-AZ in India expresspharma
May 07, 2021
Glenmark Pharmaceuticals announced the launch of Ryaltris-AZ Nasal Spray, a novel fixed-dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg, for the treatment of moderate to severe allergic rhinitis, in India.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page